AKT1 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ALK status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AXL is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and hepatocellular carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CBL is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CBL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF19 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGF4 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

GRB2 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GRB2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 4 clinical trials for hepatocellular carcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS status and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCL1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 6 clinical trials for hepatocellular carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MET status and hepatocellular carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

MTOR is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PLCG2 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PLCG2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 3 clinical trials for hepatocellular carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RICTOR status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RPTOR status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAT3 is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TNFRSF10B is an inclusion eligibility criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF10B status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].